-+ 0.00%
-+ 0.00%
-+ 0.00%

MINERVA NEUROSCIENCES ANNOUNCES FIRST PATIENT SCREENED IN GLOBAL PHASE 3 CONFIRMATORY TRIAL OF ROLUPERIDONE FOR THE TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA

Reuters·03/31/2026 20:05:00

Please log in to view news